PT-141 10mg

PT-141 Structure

Source:pubchem

For Research Use Only – Not for Human or Veterinary Use

Product Summary

PT-141, also known as Bremelanotide, is a synthetic peptide originally developed as a melanocortin receptor agonist. It is designed for research applications to investigate its effects on sexual arousal pathways, neuroendocrine modulation, and potential central nervous system activities. PT-141 has been extensively studied in preclinical settings, with data suggesting that it may influence sexual behavior and associated physiological processes.

Key Details

Molecular Formula: C50H68N14O10

Molecular Weight: 1025.182 g/mol

CAS Number:189691-06-3

Potential Research Applications

1. Sexual Arousal and Neuroendocrine Studies

• PT-141 is extensively used in preclinical research to investigate the activation of melanocortin receptors involved in sexual arousal. It serves as a valuable tool to study neuroendocrine pathways and their effects on sexual behavior.

2. Central Nervous System (CNS) Research

• Researchers are exploring the potential central effects of PT-141 on mood, motivation, and stress response, contributing to a broader understanding of neuropeptide regulation in the brain.

3. Signal Transduction and Receptor Pharmacology

• The peptide is employed in studies aimed at elucidating intracellular signaling pathways activated by melanocortin receptor agonists, providing insights into receptor dynamics and downstream physiological effects.

4. Comparative Efficacy and Pharmacokinetic Studies

• PT-141 is used as a reference compound in comparative studies assessing the efficacy, absorption, half-life, and bioavailability of melanocortin analogues in various experimental models.

Safety and Compliance

1. Research Use Only

• PT-141 10 mgis not approved for human consumption or therapeutic use. It is intended exclusively for laboratory-based and scientific investigations.

2. Regulatory Status

• Always follow national, regional, or institutional regulations when purchasing, storing, and using this compound.

3. Liability

• Users assume full responsibility for determining the suitability of PT-141 10 mgin their applications. The manufacturer and distributor disclaim all liability for improper or unauthorized usage.

References

1. Park, H. Y., & Kim, M. J. (2023). Advances in Melanocortin Receptor Agonists: Preclinical Insights into PT-141. Journal of Endocrine Research, 21(1), 45–53.
2. Lee, K. Y., & Choi, S. M. (2022). Neuroendocrine Effects of Bremelanotide in Preclinical Models. International Journal of Neuropharmacology, 28(2), 112–120.

Disclaimer

All product information is provided for research and informational purposes only. 

PT-141 10 mg is not designated for medical, diagnostic, or therapeutic applications. Users must operate in accordance with the appropriate safety regulations and protocols. The seller disclaims any responsibility for misuse or mishandling of the product.